Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window

MADISON, Wis., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that its...
August 14, 2017 16:45 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance

MADISON, Wis., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces financial...
August 08, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients

MADISON, Wis., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces its lead PDC...
August 03, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance

MADISON, Wis., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that management...
August 01, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors

MADISON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces the initiation of a...
June 06, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference

MADISON, Wis., June 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that president and CEO Jim Caruso will be presenting...
May 30, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the LD Micro Invitational Conference

MADISON, Wis., May 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 7th annual LD Micro...
May 18, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Three Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings

MADISON, Wis., May 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces preclinical...
May 11, 2017 16:05 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance

MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial...
May 02, 2017 08:30 ET | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance

MADISON, Wis., May 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that management...